Keyphrases
Glucagon-like
100%
Glucose-dependent Insulinotropic Polypeptide Receptor
100%
Agonism
100%
Glucagon Secretion
100%
Glucose-dependent Insulinotropic Polypeptide
50%
Glucagon
33%
Weight Loss
33%
Postprandial Insulin
16%
Unimolecular
16%
Pharmacology
16%
Therapeutic Effect
16%
Cell Secretion
16%
Type 2 Diabetic Patients
16%
Glucose Level
16%
Insulin Secretion
16%
Glycemic Control
16%
Plasma Glucose
16%
Clinical Trials
16%
Incretin Physiology
16%
Obese Patients
16%
Obesity Treatment
16%
Mechanistic Insight
16%
Means of Control
16%
Meal Ingestion
16%
Low Glucose
16%
High Dose
16%
Antidiabetic Treatment
16%
Alpha Cell
16%
Once-weekly
16%
Incretin Hormones
16%
Hemoglobin A1c (HbA1c)
16%
Incretin
16%
Medicine and Dentistry
Receptor
100%
Glucagon Like Peptide 1
100%
Gastric Inhibitory Polypeptide
100%
Glucagon Release
100%
Incretin
66%
Glucagon
33%
Gut
16%
Clinician
16%
Cellular Secretion
16%
Hemoglobin A1c
16%
Drug Megadose
16%
Obesity
16%
Clinical Trial
16%
Insulin Release
16%
Patient with Type 2 Diabetes
16%
Glycemic Control
16%
Therapy Effect
16%
Body Weight Loss
16%
Food Intake
16%
Biochemistry, Genetics and Molecular Biology
Gastric Inhibitory Polypeptide Receptor
100%
Glucagon Release
100%
Glucagon-Like Peptide-1
100%
Incretin
66%
Gastric Inhibitory Polypeptide
50%
Glucagon
33%
Receptor Agonists
33%
Insulin Release
16%
Glycosylated Hemoglobin
16%
Cellular Secretion
16%
Glucose Blood Level
16%
Glucose Level
16%
Glycemic Control
16%
Clinical Trial
16%
Drug Megadose
16%
Body Weight Loss
16%
Ingestion
16%